The perception of GLP-1s — and the people who use them — is getting better, but work still must be done to avoid stigma.
New insurance formulary trims costs of Alzheimer's and cancer therapies and marks a small win for global novel drug makers ...
AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon to announce agreements ...
Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.
From an Eli Lilly campus where pharmaceuticals are made to a new medical school and innovation district, the Charlotte region ...
The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...
The Chosun Ilbo on MSN
US bio-security act passes, South Korean firms poised to benefit
The U.S. Bio-Security Act has been passed. According to KoreaBio’s Bioeconomy Research Center on the 19th, U.S. President ...
The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...
On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 ...
Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...
Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...
The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback